ANYONE who can read can see that SQNM patented a gene, and TROV patents are not the same. It's like oil. One can't patent oil, however if you take the used oil out of the car and referbish it; that process is IP. So enuff said on wether the patants are worth something. Second this insider sells at 8$. A mere pitence of the shares this Dr. has were sold. No argument against TROV hold up, and I would argue simple end of year, that time of the cycle, selling is the ONLY reason for TROVagenes slide.
MEDSTUDY is a horses ars, and anyone who believes his garbage will loose on a fantastic way to diagnose the results of cancer treatment. Testing urine will be the standard, it has to be. Look at all the pros and cons. Clearly the Pros outweigh anything else out there. TROV can't diagnose all cancers but the one they can have a huge general population, and the patents are a lock. Looking forward to the HPV studies, and colaborations to come. SQNM hit $30, and the lead Dr. sold out. TROV will hit 30$, and then I will reexamine my position. Till then TROV is a buy. Insider selling is nothing here, and Paul Billings on the board is trmendous.
TROV reconstructs DNA from snippets of smaller DNA in the urine. This process is not naturally occurring, it has to be reconstructed, and therefore is a valid patent. The snippets are naturally occurring, but putting them together to see if the treatment is working is an intellectual property. Think will ya. kenn